AmFAR, Foundation for AIDS Research: TAHOD Tuberculosis Study

Project Timeline

The use of highly active antiretroviral therapy (HAART) has led to dramatic reductions in morbidity and mortality in HIV patients. However, tuberculosis (TB) remains a common opportunistic infections and a major cause of death among patients with HIV, especially in sub-Saharan African and Asian countries, where there is a high background prevalence of TB.

The risk of TB in HIV-infected patients and the impact of TB diagnosis on disease progression in HIV infected patients have been well described in Africa. The Asia-Pacific region has a large burden of both tuberculosis, with nearly 5 million prevalent cases and over 3 million new cases in 2006, and HIV, with an estimated 5 million people living with HIV and 380,000 new infections occurring in 2007. It is estimated that 2.5 million people are living with both infections in the region. Despite the importance of these inter-related epidemics in the region, few studies have evaluated the risk of TB or its prognostic impact in patients with HIV.

Using data from The TREAT Asia HIV Observational Database (TAHOD), a multicentre prospective cohort study involving 17 clinical sites in the Asia-Pacific region, this paper aims to assess:

1) The risk of, and factors associated with, TB diagnosis among TAHOD patients with prospective follow up;

2) The prognostic significance of TB diagnosis on overall survival.

External Links


Other Clinical Research

Strategic Timing of Anti-Retroviral Treatment (START Study)
The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...
Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach
Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)
First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...